Psilocybin for Methamphetamine Addiction

This open-label, single-arm early Phase I trial (n=20) will assess the feasibility, tolerability, and potential effectiveness of a single 25 mg dose of psilocybin in promoting abstinence from methamphetamine in adults undergoing residential addiction treatment.

Conducted by Dr Kevin Murnane at Louisiana State University Health Sciences Center Shreveport, this pilot study targets individuals diagnosed with methamphetamine use disorder who have expressed a desire for complete abstinence and are already in treatment.

Participants will undergo extensive screening, baseline assessments, and three preparatory sessions (two of which may be virtual) before receiving the psilocybin dose. The administration session, lasting 6–8 hours, will be monitored by trained staff and include cardiovascular safety checks. Follow-up care includes two integration sessions and multiple telehealth and in-person check-ins over 120 days to assess outcomes such as abstinence, craving reduction, mood, cognitive function, and quality of life. The study will also explore the subjective aspects of the psychedelic experience and its impact on long-term recovery. This research may inform future treatments for stimulant addiction in underserved populations.

Topic Addiction
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.